Breakthru Advisory Services’s AbbVie ABBV Stock Holding History

Breakthru Advisory Services’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,327	Closed	-$289K	–	16
2026 Q1	$289K	Sell	1,327 -419	-24%	-$92.9K	0.46%	41
2025 Q4	$399K	Buy	1,746 +40	+2%	+$9.11K	0.25%	40
2025 Q3	$395K	Buy	+1,706	New	+$347K	0.26%	40
2025 Q1	–	Sell	-1,608	Closed	-$286K	–	11
2024 Q4	$286K	Buy	+1,608	New	+$296K	0.26%	43

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Breakthru Advisory Services's ABBV Position: Q2 2026 in Review

Breakthru Advisory Services sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 1,327 shares — an estimated $289K sold.

Breakthru Advisory Services first reported a position in ABBV in Q4 2024 and held it in 4 quarters. The position peaked at $399K in Q4 2025. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Breakthru Advisory Services reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Breakthru Advisory Services sold 1,327 AbbVie shares in Q2 2026, an estimated $289K.
Breakthru Advisory Services first reported a position in AbbVie in Q4 2024 and held it in 4 quarters.
Breakthru Advisory Services's AbbVie position peaked at $399K in Q4 2025.
4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Breakthru Advisory Services's 13F filing for Q2 2026, filed 23 Jul 2026.